Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by CUR2004on Jun 09, 2011 8:59pm
222 Views
Post# 18696564

New study

New studyThe “New” Prostate Cancer InfoLink would note, however, that the proposed algorithm still tells us nothing about the ability to differentiate between clinically significant and clinically indolent forms of prostate cancer. The value of the proposed algorithm at this time is restricted to the elimination of unnecessary biopsies. This is a worthy goal in itself, but only addresses part of the problem. In addition, the proposed algorithm clearly needs to be tested prospectively as opposed to retrospectively before it could be applied to clinical decision making on an ongoing basis.me/low grade cancer.
Bullboard Posts